Still hungry on a GLP-1

What the labels promise, and what they leave out

Section 12.2 of the Wegovy® and Zepbound® labels says semaglutide and tirzepatide lower calorie intake and that the effect is likely mediated by appetite ^[1][5]. The Foundayo™ label says orforglipron decreases food intake, probably through decreased appetite ^[7]. The labels also note that GLP-1 receptors sit in brain areas involved in regulating appetite.

None of this is a promise that hunger will disappear. The statements describe an effect measured as less food eaten on average across a trial, not how hungry any one person will feel on a given afternoon. The European documents go further and describe more fullness, less hunger and fewer cravings with semaglutide and tirzepatide, but those are averages too ^[8][9].

How many people noticed less appetite

Decreased appetite appears as a side effect in some labels and not in others. The table gathers what each document says. The rows come from different trials, populations and counting rules, so they cannot be compared with one another.

What clinical studies measured

The European Wegovy® information describes a 20-week phase 1 trial in which people ate 35% less at a meal where they could eat as much as they liked, on semaglutide compared with placebo ^[8]. For tirzepatide, a randomised phase 1 trial in 114 adults without diabetes found lower intake at a test lunch after three weeks, along with less overall appetite, fewer cravings, less perceived hunger and a weaker tendency to overeat, though deliberate restraint of eating did not change ^[10].

These trials are short and measure eating in a laboratory setting, and the tirzepatide trial was run with the manufacturer. They show a clear average effect, and say little about why one person stays hungry while another barely thinks about food.

Why hunger can still come through

Some explanations rest on the labels themselves. Every one of these medicines starts low and steps up; the Zepbound® label describes its first dose as a starting dose that is not approved for maintenance and allows each increase only after at least four weeks, and the Wegovy® label also steps up every four weeks, both to reduce stomach side effects ^[1][5]. In the early weeks you may not yet be on the dose your prescriber plans to keep you on. The Mounjaro®, Zepbound®, Foundayo™ and Trulicity® labels add that the delay in stomach emptying is greatest after the first dose and lessens over time ^[4][5][6][7]. They do not say this brings hunger back, so treat it as a possible piece of the picture, not a proven cause.

Other explanations are suggested but not measured. The authors of a 2025 advisory from four US societies in lifestyle medicine, nutrition and obesity write that, in their clinical experience, low interest in food can lead people to go several hours without eating, and that waiting until they are very hungry can pull them towards sugars and refined starches; nausea, they add, can trigger cravings for comfort foods ^[13]. This is expert observation, not a trial result.

Response also varies. In STEP 1, 86.4% of people on semaglutide lost at least 5% of their weight by week 68, against 31.5% on placebo, so a minority did not reach that mark ^[12]. A 2026 narrative review estimates non-response in obesity trials at about 10% of participants, possibly more in everyday practice, and finds that no baseline characteristic reliably predicts it; how someone responds early in treatment is the most useful guide so far ^[11].

Other reasons for feeling hungrier

MedlinePlus lists several causes of increased appetite that have nothing to do with a GLP-1 medicine: anxiety, some medicines such as corticosteroids, cyproheptadine and tricyclic antidepressants, bulimia, diabetes, an overactive thyroid including Graves disease, low blood sugar and premenstrual syndrome ^[14]. It notes that increased appetite can come and go or last a long time depending on the cause.

NIDDK points out that a lifestyle programme can address eating triggers and not getting enough sleep alongside eating and activity habits, and that weight management medicines are meant to support such a programme rather than replace it ^[16]. Patterns help here: hunger that always arrives at the same hour, after a short night or in stressful weeks tells your clinician something different from hunger that never lets up.

When hunger is a warning sign

If you have type 2 diabetes and use insulin or a sulfonylurea as well, note that the Ozempic® and Wegovy® Medication Guides list hunger among the signs of low blood sugar, together with sweating, shakiness, dizziness, a fast heartbeat, confusion and irritability ^[1][2]. The Wegovy® Medication Guide adds that in people with type 2 diabetes low blood sugar can be both common and serious, and asks them to check their blood sugar before and during treatment ^[1].

MedlinePlus explains that hunger and sweating can appear when blood sugar is only slightly low, and that more severe symptoms come at lower levels ^[15]. If hunger arrives suddenly with any of these signs, follow the plan your care team gave you and tell your prescriber. Our article on low blood sugar covers this in more detail.

What the sources say may help

• Ask about the dose schedule: whether you are still on a starting or step-up dose is a question your prescriber can answer from the label ^[1][5].
• Review your other medicines: MedlinePlus says that if a medicine is increasing appetite, a provider may change the dose or try another, and that you should not stop a medicine without talking to them first ^[14].
• Look at sleep and triggers: NIDDK names both as part of a lifestyle programme that medicines are meant to support ^[16].
• Consider a dietitian: the 2025 advisory describes registered dietitians as helping with food choices, meal timing, portions and self-monitoring alongside GLP-1 treatment ^[13].
• MedlinePlus lists emotional support, and in some cases counselling, as home care for increased appetite ^[14].

Questions for your clinician

• Am I still on a starting or step-up dose, and when will we review it?
• Is hunger at this stage something to expect, or worth looking into?
• Could any of my other medicines be increasing my appetite?
• If I take insulin or a sulfonylurea, how do I tell hunger from low blood sugar, and what is my plan?
• Would a dietitian help me plan meals that fit my appetite and my medicine?

Wegovy®, Ozempic® and Rybelsus® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® and Trulicity® are registered trademarks and Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.

When to get help